XAIR Beyond Air

Beyond AirTM Schedules Third Fiscal Quarter 2020 Financial Results Conference Call and Webcast

Beyond AirTM Schedules Third Fiscal Quarter 2020 Financial Results Conference Call and Webcast

Call scheduled for Friday, February 7th at 11:00 am Eastern Time

GARDEN CITY, New York and REHOVOT, Israel, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced it will report financial results for its third fiscal quarter ended December 31, 2019 before the market open on Friday, February 7, 2020 and will host a conference call and webcast on at 11:00 am Eastern Time the same day.

Conference Call & Webcast
Friday, February 7th @ 11:00 am ET
Domestic: 877-407-0784
International: 201-689-8560
Passcode: 13698390
Webcast: 

About Beyond Air, Inc.

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System (LungFit™) that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The Beyond Air NO Delivery System can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose.  The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for lower respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and severe lung infections such as nontuberculous mycobacteria (NTM). For more information, visit .

CONTACT

Steven Lisi, Chief Executive Officer

Beyond Air, Inc.

Bob Yedid

LifeSci Advisors, LLC



(646) 597-6989

 

EN
22/01/2020

Underlying

XAIRBeyond Air

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Beyond Air

 PRESS RELEASE
Free
XAIR BEYOND AIR

Beyond Air® Signs New International LungFit PH® Distribution Agreement...

Beyond Air® Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and Brazil Distribution network coverage expanded to a total of 39 countries GARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the recent signing of several key international distribution agreements for LungFit® PH, expanding its network to include Germany, Bra...

December 17, 2025 1 EN
 PRESS RELEASE
Free
XAIR BEYOND AIR

Beyond Air® Announces Transition of Chief Financial Officer

Beyond Air® Announces Transition of Chief Financial Officer Launched search for permanent successor GARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Doug Larson has resigned as Chief Financial Officer to pursue another opportunity. Mr. Larson will continue to serve as CFO through December 5, 2025, at which time the CFO responsibilities at the Company...

November 26, 2025 1 EN
 PRESS RELEASE
Free
XAIR BEYOND AIR

Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and P...

Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025 Achieves certificate for Medical Device Single Audit Program (MDSAP) Updated fiscal year 2026 revenue guidance to $8 – $10 million Conference call at 4:30 p.m. ET today, November 10th GARDEN CI...

November 10, 2025 1 EN
 PRESS RELEASE
Free
XAIR BEYOND AIR

Beyond Air® Secures Up to $32 Million to Accelerate Growth

Beyond Air® Secures Up to $32 Million to Accelerate Growth Enters agreements for a $12 million promissory note and a $20 million equity line of credit with Streeterville Capital Proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025, including $12 million from the promissory note Extends cash runway into calendar 2027 GARDEN CITY, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the p...

November 5, 2025 1 EN
 PRESS RELEASE
Free
XAIR BEYOND AIR

Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conf...

Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its second fiscal quarter ended September 30, 2025 on Monday, November 10, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm E...

October 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch